Osteoarthritis (OA) is the most common type of joint disordered which is called degenerative joint disease (DJD) (
1). DJD is a kind of disease of the articular surface which is associated with progressive degeneration of the articular surface, or also synovial layer, relative ligaments, and the subchondral areas. The incidence and prevalence of DJD vary through of the world and between different populations. Based on previous studies, about 10 percent of men and 18 percent of women more than 60 years old are involved by degenerative joint disease (
1). Synovial inflammation enables the remodeling and repairing of affected tissues. However, the causes of OA are unclear, but it is clarified that OA sometimes started with articular surface damage because of mechanical injuries and accumulation of inflammatory mediators which are secreted from synovial cells into the damaged cartilage surface and then lead to cartilage metabolism defects. After the joint injury, chondrocytes attempt to repair articular surface with increases of the production of proteoglycans and collagen and connective tissue around of joint. However, during this period, some enzymes released of inflammatory cells that begin to degrade cartilage of articular surface. Inflammatory mediators originated from inflammatory cells degrade the chondrocytes and synovial lining cells lead to breaking down the articular cartilage lining. The articular surface and all surrounded tissues are affected by OA. During this degrading process, the synovium becomes inflamed and fibrotic. Synovial fluid (SF) accumulated in articular synovial space. This fluid is characterized by less viscosity in greater volume. Also, periarticular tissues including relative tendons as well as ligaments are in stress. The joints become stiff and less mobile. CD163 is a hemoglobin/haptoglobin scavenger receptor family (
2). The CD163 is expressed on cytoplasm membrane of monocytes and macrophages. Some previous studies reported that the high expression on existent monocytes and macrophages in meanwhile of advanced stages of OA (
3,
4). The CD163 expression is increased by inflammatory mediators such as glucocorticoids, IL-10, IL-6, and finally the macrophage colony-stimulating factor; it is down-regulated by TNFα, lipopolysaccharide (LPS), and interferon-γ (IFNγ) (
2,
5). However, CD163 biomarker has been reacted during the inflammatory process by about three different pathways, 1-In vitro, The CD163 can be secreted of the cell membrane by metalloproteinase enzyme in response to lipopolysaccharides and becomes soluble CD163 (sCD163). However ,the CD163 (sCD163) has been circulated in plasma (
4-
6). The sCD163 considers decreasing activation and proliferation of some inflammatory function in vitro (
7,
8). 2-CD163 added to a kind of protein tyrosine kinase and casein kinase II-dependent signal that leads to mobilization of calcium, inositol triphosphate production, and some pro-inflammatory mediators such as IL-1β, IL-6, and granulocyte-macrophage colony-stimulating factor (
9,
10). 3-CD163 is a hemoglobin/haptoglobin scavenger receptor complexes, with the highest functional affinity for hemoglobin/haptoglobin complexes (
11). However, haptoglobin dependent modulation of oxidative stress molecules, prostaglandin synthesis, and angiogenesis started by the inflammatory process (
12,
13).